Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor I. Binding characteristics
Abstract
Glimepiride is a novel sulfonylurea drug for treatment of non-insulin-dependent diabetes mellitus with higher blood sugar lowering efficacy in diabetic patients than glibenclamide raising the question whether this characteristics is in line with different binding of glimepiride and glibenclamide to the beta-cell sulfonylurea receptor. Scatchard plot analysis of [3H]sulfonylurea binding to membranes isolated from rat beta-cell tumors and (RINm5F) insulinoma cells and to RINm5F cells demonstrated that glimepiride has a 2.5-3-fold lower affinity than glibenclamide. This corresponded well to the 8-9-fold higher koff and 2.5-3-fold higher kon rates of glimepiride compared to glibenclamide as revealed by the dissociation and association kinetics of [3H]sulfonylurea binding and the Kd values calculated thereof. In agreement, the concentrations required for half-maximal displacement of [3H]sulfonylurea bound to beta-cell membranes were significantly higher for glimepiride compared to glibenclamide. However, the binding affinity of glimepiride measured by both equilibrium binding and kinetic binding studies upon solubilization of beta-cell tumor membranes and RINm5F cell membranes increased up to the value for glibenclamide. This was primarily based on a drastic decrease of the dissociation rate constant of glimepiride whereas the kinetics of glibenclamide binding remained largely unaffected upon solubilization. These data suggest that the Kd value alone is not sufficient for characterization of a sulfonylurea drug, since the kinetic binding parameters may also determine its acute blood sugar lowering efficacy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Glimepiride, a long-acting sulfonylurea, may partly fulfil the role of a sulfonylurea with good glycemic control and low risk of hypoglycemia as it has a lower affinity for the β-cell receptor than glyburide, and its insulin secretory capacity is lower in both the fasting and postprandial states.
“Glimepiride, a long-acting sulfonylurea, may partly fulfil this role as it has a lower affinity for the -cell receptor than glyburide (117), and its insulin secretory capacity is lower in both the fasting (118) and postprandial (119) states.”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Glucose induces closure of single potassium channels in isolated rat pancreatic β-cells
Ashcroft, F. M., Harrison, D. E., & Ashcroft, S. J. H. (1984) · Nature · doi:10.1038/312446a0 · Cited by 1,113 · see citing works
Weiland, G. A., & Molinoff, P. B. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90324-6 · Cited by 555 · see citing works
The sulphonylurea receptor may be an ATP-sensitive potassium channel.
Sturgess, N., Cook, D., Ashford, M., & Hales, C. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90403-9 · Cited by 535 · see citing works
Oates, J. A., Wood, A. J. J., & Gerich, J. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911023211805 · Cited by 476 · see citing works
Schmid‐Antomarchi, H., de Weille, J. R., Fosset, M., & Lazdunski, M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47664-8 · Cited by 445 · see citing works
Regulation of Adenylyl Cyclase-Coupled beta-Adrenergic Receptors
Benovic, J., Bouvier, M., Caron, M. G., & Lefkowitz, R. J. (1988) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.04.110188.002201 · Cited by 395 · see citing works
Sulfonylurea Receptors, Ion Channels, and Fruit Flies
Boyd, A. E. (1988) · Diabetes · doi:10.2337/diab.37.7.847 · Cited by 281 · see citing works
Ashcroft, S. J. H., & Ashcroft, F. M. (1992) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(92)90008-y · Cited by 260 · see citing works
Regulation of immunoreactive-insulin release from a rat cell line (RINm5F)
Praz, G., Halban, P. A., Wollheim, C. B., Blondel, B., Strauss, A. J., & Renold, A. E. (1983) · Biochemical Journal · doi:10.1042/bj2100345 · Cited by 238 · see citing works
The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects
Kolterman, O. G., Gray, R. S., Shapiro, G., Scarlett, J. A., Griffin, J., & Olefsky, J. M. (1984) · Diabetes · doi:10.2337/diab.33.4.346 · Cited by 213 · see citing works
Comparison of Plasma Insulin Levels Following Administration of Tolbutamide and Glucose
Yalow, R. S., Black, H., Villazon, M., & Berson, S. A. (1960) · Diabetes · doi:10.2337/diab.9.5.356 · Cited by 207 · see citing works
Panten, U., Burgfeld, J., Goerke, F., Rennicke, M., Schwanstecher, M., Wallasch, A., Zünkler, B. J., & Lenzen, S. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90327-4 · Cited by 173 · see citing works
Characterization of the sulfonylurea receptor on beta cell membranes.
Gaines, K. L., Hamilton, S. L., & BOYD, A. E. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69106-9 · Cited by 116 · see citing works
Schmid-Antomarchi, H., de Weille, J., Fosset, M., & Lazdunski, M. (1987) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/0006-291x(87)90684-x · Cited by 104 · see citing works
Aguilar‐Bryan, L., Nelson, D. A., Vu, Q. A., Humphrey, M. B., & BOYD, A. E. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39060-x · Cited by 100 · see citing works
Interaction of sulfonylurea with the pancreatic B-cell
Gylfe, E., Hellman, B., Sehlin, J., & Täljedal, I. (1984) · Cellular and Molecular Life Sciences · doi:10.1007/bf01971460 · Cited by 100 · see citing works
Kramer, W., Müller, G. A., Girbig, F., Gutjahr, U., Kowalewski, S., Hartz, D., & Summ, H.-D. (1994) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(94)90178-3 · Cited by 84 · see citing works
Self-citationInsulin, Glucagon, and Somatostatin Receptors on Cultured Cells and Clones from Rat Islet Cell Tumor
Bhathena, S. J., Oie, H. K., Gazdar, A. F., Voyles, N. R., Wilkins, S. D., & Recant, L. (1982) · Diabetes · doi:10.2337/diab.31.6.521 · Cited by 84 · see citing works
Special pharmacology of the new sulfonylurea glimepiride.
Geisen, K. (1988) · PubMed · Cited by 80 · see citing works
Specific receptors for sulfonylureas in brain and in a B-cell tumor of the rat
Kaubisch, N., Hammer, R., Wollheim, C. B., Renold, A. E., & Offord, R. E. (1982) · Biochemical Pharmacology · doi:10.1016/0006-2952(82)90363-x · Cited by 75 · see citing works
Kramer, W., Oekonomopulos, R., Pünter, J., & Summ, H.-D. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)81155-4 · Cited by 75 · see citing works
Self-citationThe role of ion channels in insulin secretion
Boyd, A. E. (1992) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240480303 · Cited by 72 · see citing works
Increased cytosolic calcium. A signal for sulfonylurea-stimulated insulin release from beta cells.
Nelson, T. Y., Gaines, K. L., Rajan, A. S., Berg, M., & BOYD, A. E. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61549-2 · Cited by 67 · see citing works
Internalization of 3H-glibenclamide in pancreatic islet cells
Carpentier, J. L., Sawano, F., Ravazzola, M., & Malaisse, W. J. (1986) · Diabetologia · doi:10.1007/bf00454887 · Cited by 62 · see citing works
Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics.
Geisen, K., Hitzel, V., Ökomonopoulos, R., Pünter, J., Weyer, R., & Summ, H.-D. (1985) · PubMed · Cited by 62 · see citing works
Self-citationMüller, G. A., Dearey, E.-A., & Pünter, J. (1993) · Biochemical Journal · doi:10.1042/bj2890509 · Cited by 54 · see citing works
Self-citationNiki, I., Ashcroft, F., & Ashcroft, S. J. H. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)81572-8 · Cited by 54 · see citing works
Specificity of photolabeling of beta-cell membrane proteins with an 125I-labeled glyburide analog.
Nelson, D. A., Aguilar‐Bryan, L., & Bryan, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42129-1 · Cited by 47 · see citing works
The β-cell glibenclamide receptor is an ADP-binding protein
Niki, I., Nicks, J. L., & Ashcroft, S. J. H. (1990) · Biochemical Journal · doi:10.1042/bj2680713 · Cited by 45 · see citing works
Sulfonylurea Signal Transduction
BOYD, A. E., Aguilar‐Bryan, L., Bryan, J., Kunze, D. L., Moss, L. G., Nelson, D. A., Rajan, A. S., Raef, H., XIANG, H., & Yaney, G. C. (1991) · Elsevier eBooks · doi:10.1016/b978-0-12-571147-0.50013-5 · Cited by 30 · see citing works
Niki, I., Welsh, M., Berggren, P., Hubbard, P. C., & Ashcroft, S. J. H. (1991) · Biochemical Journal · doi:10.1042/bj2770619 · Cited by 23 · see citing works
Niki, I., Kelly, R., Ashcroft, S. J. H., & Ashcroft, F. (1989) · Pflügers Archiv · doi:10.1007/bf00373140 · Cited by 19 · see citing works
Modulation of [3H]glibenclamide binding to cardiac and insulinoma membranes
French, J. F., Riera, L. C., Mullins, U. L., & Sarmiento, J. G. (1991) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/s0922-4106(05)80033-1 · Cited by 14 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [22][22] Chick, W.L., Warren, S., Chute, R.N., Like, N.A., Lauris, V. and Kitchen, K. (1977) Proc. Natl. Acad. Soc. USA 74, 628–632. -
Cited by
Sorted by citations
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435 · see citing works
Holstein, A., Plaschke, A., & Egberts, E. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.235 · Cited by 264 · see citing works
Sulphonylurea action revisited: the post-cloning era
Gribble, F. M., & Reimann, F. (2003) · Diabetologia · doi:10.1007/s00125-003-1143-3 · Cited by 284 · see citing works
Klepzig, H. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1242 · Cited by 224 · see citing works
Impairment of Myocardial Protection in Type 2 Diabetic Patients
Lee, T., & Chou, T. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020904 · Cited by 170 · see citing works
Langtry, H. D., & Balfour, J. A. B. (1998) · Drugs · doi:10.2165/00003495-199855040-00007 · Cited by 165 · see citing works
Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R. (2000) · PubMed · Cited by 126 · see citing works
The role of glimepiride in the effective management of Type 2 diabetes
Davis, S. N. (2004) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.07.001 · Cited by 120 · see citing works
Kalra, S., Aamir, A., Raza, A., Das, A., Khan, A. A., Shrestha, D., Qureshi, M., Fariduddin, M., Pathan, M. F., Jawad, F., et al. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163171 · Cited by 112 · see citing works
Glimerpiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience
Massi‐Benedetti, M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80109-1 · Cited by 100 · see citing works
Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans
Bijlstra, P. J., Lutterman, J. A., Rüssel, F. G. M., Thien, T., & Smits, P. (1996) · Diabetologia · doi:10.1007/bf00400658 · Cited by 96 · see citing works
Dalem, J. D. R.-V., Brouwers, M. C. G. J., Stehouwer, C. D. A., Krings, A., Leufkens, H. G. M., Driessen, J. H. M., de Vries, F., & Burden, A. M. (2016) · BMJ · doi:10.1136/bmj.i3625 · Cited by 96 · see citing works
Glimepiride: Role of a New Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus
Campbell, R. K. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17360 · Cited by 91 · see citing works
Müller, G. A. (2000) · Molecular Medicine · doi:10.1007/bf03401827 · Cited by 91 · see citing works
Self-citationKramer, W., Müller, G. A., Girbig, F., Gutjahr, U., Kowalewski, S., Hartz, D., & Summ, H.-D. (1994) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(94)90178-3 · Cited by 84 · see citing works
Self-citationSuzuki, K., Yanagawa, T., Shibasaki, T., Kaniwa, N., Hasegawa, R., & Tohkin, M. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.09.019 · Cited by 81 · see citing works
Guerra, S. D., Marselli, L., Lupi, R., Boggi, U., Mosca, F., Benzi, L., Prato, S. D., & Marchetti, P. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.05.001 · Cited by 80 · see citing works
Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia
Holstein, A., Plaschke, A., Hammer, C., & Egberts, E. ‐. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0592-4 · Cited by 76 · see citing works
Glimepiride block of cloned β‐cell, cardiac and smooth muscle KATP channels
Song, D., & Ashcroft, F. M. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704062 · Cited by 76 · see citing works
Schade, D. S., Jovanovic, L. G., & Schneider, J. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04471.x · Cited by 71 · see citing works
Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39254-7 · Cited by 78 · see citing works
The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents
Rosak, C. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00207-0 · Cited by 70 · see citing works
Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
Basit, A., Riaz, M., & Fawwad, A. (2012) · PubMed Central · doi:10.2147/hiv.s33194 · Cited by 70 · see citing works
Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions
Holstein, A., & Beil, W. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902806424 · Cited by 62 · see citing works
Müller, G. A., Wied, S., Wetekam, E.-M., Crecelius, A. C., Unkelbach, A., & Pünter, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90369-7 · Cited by 61 · see citing works
Self-citationSustained Enhancement of Ca2+ Influx by Glibenclamide Induces Apoptosis in RINm5F Cells
Iwakura, T., Fujimoto, S., Kagimoto, S., Inada, A., Kubota, A., Someya, Y., Ihara, Y., Yamada, Y., & Seino, Y. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2616 · Cited by 58 · see citing works
Weitgasser, R., Lechleitner, M., Luger, A., & Klingler, A. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00254-1 · Cited by 56 · see citing works
The role of glimepiride in the treatment of type 2 diabetes mellitus
Briscoe, V. J., Griffith, M. L., & Davis, S. N. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903512955 · Cited by 54 · see citing works
Drug-induced hypoglycaemia in type 2 diabetes
Inkster, B., Zammitt, N. N., & Frier, B. M. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.694424 · Cited by 52 · see citing works
Holstein, A., Beil, W., & Kovacs, P. L. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.722619 · Cited by 50 · see citing works
Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia
Szoke, E., Gosmanov, N. R., Sinkin, J. C., Nihalani, A., Fender, A. B., Cryer, P. E., Meyer, C., & Gerich, J. E. (2005) · Metabolism · doi:10.1016/j.metabol.2005.07.009 · Cited by 45 · see citing works
Postprandial Hyperglycemia in Patients with Type 2 Diabetes Mellitus
Sudhir, R., & Mohan, V. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00004 · Cited by 45 · see citing works
The molecular interaction of sulfonylureas with β-cell ATP-sensitive K+-channels
Kramer, W., Müller, G. A., Girbig, F., Gutjahr, U., Kowalewski, S., Hartz, D., & Summ, H.-D. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01076-p · Cited by 44 · see citing works
Self-citationEl-Reyani, N. E., Bozdoǧan, Ö., Baczkó, I., Leprán, I., & Papp, J. G. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00866-8 · Cited by 38 · see citing works
The role of potassium channels in excitable cells
Edwards, G., & Weston, A. H. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01080-w · Cited by 38 · see citing works
Martin, S., Kolb, H., Beuth, J., van Leendert, R., Schneider, B., & Scherbaum, W. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1238-x · Cited by 37 · see citing works
Efficacy of glimepiride in Japanese type 2 diabetic subjects
Inukai, K., Watanabe, M., Nakashima, Y., Sawa, T., Takata, N., Tanaka, M., Kashiwabara, H., Yokota, K., Suzuki, M., Kurihara, S., et al. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.10.002 · Cited by 36 · see citing works
Holstein, A., Plaschke, A., Hammer, C., Ptak, M., Kühn, J., Kratzsch, C., Diekmann, J., Kleesiek, K., Maurer, H. H., & Egberts, E. ‐. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0697-9 · Cited by 31 · see citing works
Investigation of structure–activity relationships in a series of glibenclamide analogues
Yuriev, E., Kong, D. C. M., & Iskander, M. N. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.06.004 · Cited by 30 · see citing works
Evaluation of Effect of Nishamalaki on STZ and HFHF Diet Induced Diabetic Neuropathy in Wistar Rats
Dawane, J. S. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/21011.8752 · Cited by 20 · see citing works
Cho, H., Lee, S., Kim, Y.-G., Oh, S., Kim, J., Huh, W., Ko, J.-W., & Kim, H. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.06.014 · Cited by 19 · see citing works
Gregorio, F., Ambrosi, F., Cristallini, S., Filipponi, P., & Santeusanio, F. (1996) · Acta Diabetologica · doi:10.1007/bf00571936 · Cited by 19 · see citing works
Haemodynamic and other effects of sulphonylurea drugs on the heart.
Végh, Á., & Papp, J. G. (1996) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(96)01229-6 · Cited by 19 · see citing works
Joy, N. G., Tate, D. B., & Davis, S. N. (2015) · Metabolism · doi:10.1016/j.metabol.2015.02.006 · Cited by 14 · see citing works
Mokale, V. J., Naik, J., Verma, U., Js, P., & Yadava, S. K. (2014) · Scholarena Journal of Pharmacy and Pharmacology · doi:10.18875/2375-2262.1.104 · Cited by 14 · see citing works
Morris, A. D. (2003) · The Science of Diabetes Self-Management and Care · doi:10.1177/014572170302900309 · Cited by 14 · see citing works
Jawa, A., & Fonseca, V. A. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2004.06.001 · Cited by 14 · see citing works
Recent advances in potassium channel modulation
Edwards, G., & Weston, A. H. (1997) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8863-9_3 · Cited by 10 · see citing works
Dhua, M., Sen, K. K., & Maiti, S. (2022) · Journal of Vinyl and Additive Technology · doi:10.1002/vnl.21899 · Cited by 9 · see citing works
Mode of Action of Sulfonylureas
Panten, U., Schwanstecher, M., & Schwanstecher, C. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-09127-2_6 · Cited by 10 · see citing works
Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits
Phadatare, P. D., & Chandrashekhar, V. M. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0812-7 · Cited by 8 · see citing works
Inhibitory effect of sulfonylureas on protein phosphatase activity in rat pancreatic islets
Gagliardino, J. J., Rossi, J. P. F. C., & García, M. E. (1997) · Acta Diabetologica · doi:10.1007/s005920050057 · Cited by 8 · see citing works
Novel glimepiride derivatives with potential as double-edged swords against type II diabetes
Müller, G. A., Schulz, A., Hartz, D., Dearey, E.-A., Wetekam, E.-M., Ökonomopulos, R., Crecelius, A. C., Wied, S., & Frick, W. (2010) · Archives of Physiology and Biochemistry · doi:10.3109/13813450903575720 · Cited by 7 · see citing works
Self-citationVogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_12 · Cited by 6 · see citing works
Burkart, V., Brenner, H. H., Hartmann, B., & Kolb, H. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.3966 · Cited by 6 · see citing works
Chen, M., Song, W.-J., Wang, S., Chen, Q., Pan, P., Xu, T., Hu, G., & Zheng, Z. (2016) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmw003 · Cited by 6 · see citing works
Onuma, H., Inukai, K., Watanabe, M., Sumitani, Y., Hosaka, T., & Ishida, H. (2014) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2014.41006 · Cited by 5 · see citing works
Alshaer, W., Abbas, A. A., Thaher, Y. A., AlKhatib, H. S., Jabaiti, S., Tarawneh, O., Albuqain, R., & Abdelghany, S. M. (2025) · RSC Advances · doi:10.1039/d5ra03291a · Cited by 4 · see citing works
Dose Linearity of Glimepiride in Healthy Human Egyptian Volunteers
Helmy, S. A., Elbedaiwy, H. M., & Mansour, N. O. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.20 · Cited by 4 · see citing works
Patel, J., Moorthy, N. S. H. N., & Maiti, S. (2022) · Polymer Engineering and Science · doi:10.1002/pen.26107 · Cited by 4 · see citing works
Glimepiride (Amaryl): A review of its pharmacological and clinical profile.
Bando, K., & Yamada, Y. (2001) · Folia Pharmacologica Japonica · doi:10.1254/fpj.118.59 · Cited by 4 · see citing works
Yaseen, S., Bashir, R., Ovais, S., Rathore, P., Samim, M., & Javed, K. (2013) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2013.782300 · Cited by 4 · see citing works
The Pharmacology of Potassium Channel Superfamilies: Modulation of KATP and BKCa
Edwards, G., & Weston, A. H. (1996) · Springer eBooks · doi:10.1007/978-4-431-65952-5_9 · Cited by 3 · see citing works
Fixed combinations of hypoglycemic drugs in the treatment of patients with type 2 diabetes
Verbovoy, A. F., Verbovaya, N. I., & Dolgikh, Y. A. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-23-199-204 · Cited by 2 · see citing works
Propri??t??s pharmacologiques du glim??piride
Profozić, V., & Metelko, Ž. (1998) · Disease Management & Health Outcomes · doi:10.2165/00115677-199804001-00003 · Cited by 2 · see citing works
Vogel, H. G., Vogel, W. H., Schölkens, B. A., Sandow, J., Müller, G. A., & Vogel, W. F. (2002) · Springer eBooks · doi:10.1007/3-540-29837-1_12 · Cited by 2 · see citing works
Self-citationVogel, H. G., & Vogel, W. H. (1997) · Springer eBooks · doi:10.1007/978-3-662-03333-3_11 · Cited by 2 · see citing works
Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
Romantsova, T. I., & Maksimova, N. V. (2010) · Diabetes Mellitus · doi:10.14341/2072-0351-6017 · Cited by 1 · see citing works
Actualités dans les traitements du diabète de type 2. Les agents insulinosécréteurs
Blicklé, J. F., Andrès, E., Neyrolles, N., & Brogard, J. M. (1999) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(99)80508-6 · Cited by 1 · see citing works
Müller, G. A. (2015) · Springer eBooks · doi:10.1007/978-3-642-27728-3_158-1 · Cited by 1 · see citing works
Self-citationAs, A., & Abaeva, F. T. (2013) · Diabetes Mellitus · doi:10.14341/dm2013495-100 · Cited by 1 · see citing works
Modern antihyperglycemic therapy: safety and efficacy of glimepiride
Ruyatkina, L. A., & Юрьевич, С. М. (2012) · Diabetes Mellitus · doi:10.14341/2072-0351-5525 · Cited by 1 · see citing works
Efficacit?? clinique du glim??piride dans le diab??te de type 2
Cervantes, P. (1998) · Disease Management & Health Outcomes · doi:10.2165/00115677-199804001-00004
Characterization of Potassium Channel Binding
Scott, V. (1999) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0117s06
Zaytseva, N. V., & Jarek-Martynova, I. R. (2015) · Diabetes Mellitus · doi:10.14341/dm2015284-88
Глимепирид в современной гипогликемизирующей терапии: безопасность и эффективность
Ruyatkina, L. A., & Russian Federation (2012)
250 EFFECTS OF GLIMEPIRIDE AND GLYBURIDE ON GLUCOSE COUNTERREGULATION AND RECOVERY FROM HYPOGLYCEMIA
Gosmanov, N. R., Szoke, E., Cryer, P. E., Meyer, C., & Gerich, J. E. (2005) · Journal of Investigative Medicine · doi:10.2310/6650.2005.00006.249
Полторак, В. В., Кравчун, Н. А., Горшунская, М. Ю., & Krasova, N. S. (2014) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.1.57.2014.76425
Barna, O. N., & Pogrebnyak, E. A. (2018) · Medicine of Ukraine · doi:10.37987/1997-9894.2018.2(218).196122
Müller, G. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-05392-9_158
Self-citation
- Authors
- Müller, G., Hartz, D., Pünter, J., Ökonomopulos, R., & Kramer, W.
- Corresponding author
- Müller, Günter
- ORCID
- Müller, Günter
- Venue
- Biochimica et Biophysica Acta (BBA) - Biomembranes
- Publisher
- Elsevier BV
- Published
- 1994-05
- Volume
- 1191
- Issue
- 2
- Pages
- 267-277
- ISSN
- 0005-2736 (ISSN-L)
- OpenAlex
- W2158049984
- Cited by
- 81
- References
- 33
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 2 · 2018: 1 · 2016: 3 · 2015: 5 · 2014: 3 · 2013: 4 · 2012: 5
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochimica et Biophysica Acta (BBA) - Biomembranes (publishedVersion)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glimepiride, glibenclamide, sulfonylurea receptor, SUR1, binding kinetics, dissociation rate constant, association rate constant, type 2 diabetes
- MeSH terms
- Animals, Cell Line, Cell Membrane, Diabetes Mellitus, Type 2, Glyburide, Hypoglycemic Agents, Kinetics, Pancreas, Receptors, Drug, Sulfonylurea Compounds, Tritium, Potassium Channels, ATP-Binding Cassette Transporters, Potassium Channels, Inwardly Rectifying, Rats, Sulfonylurea Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
